Balyasny Asset Management
REGN icon

Balyasny Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Balyasny Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$773K Sell
1,000
-36,600
-97% -$28M ﹤0.01% 2188
2025
Q4 		$29M Buy
37,600
+6,000
+19% +$4.07M 0.04% 551
2025
Q3 		$17.8M Sell
31,600
-12,900
-29% -$7.29M 0.02% 768
2025
Q2 		$23.4M Sell
44,500
-10,900
-20% -$6.08M 0.04% 609
2025
Q1 		$35.1M Sell
55,400
-2,700
-5% -$1.86M 0.06% 402
2024
Q4 		$41.4M Sell
58,100
-6,500
-10% -$5.45M 0.06% 380
2024
Q3 		$67.9M Sell
64,600
-3,900
-6% -$4.34M 0.11% 216
2024
Q2 		$72M Buy
68,500
+5,700
+9% +$5.53M 0.13% 196
2024
Q1 		$60.4M Sell
62,800
-5,000
-7% -$4.75M 0.11% 254
2023
Q4 		$59.5M Buy
67,800
+57,400
+552% +$47.3M 0.11% 236
2023
Q3 		$8.56M Sell
10,400
-500
-5% -$393K 0.02% 905
2023
Q2 		$7.83M Buy
10,900
+2,900
+36% +$2.24M 0.02% 885
2023
Q1 		$6.57M Hold
8,000
– – 0.02% 963
2022
Q4 		$5.77M Buy
8,000
+1,300
+19% +$959K 0.02% 960
2022
Q3 		$4.62M Buy
6,700
+5,300
+379% +$3.34M 0.01% 1039
2022
Q2 		$828K Buy
+1,400
New +$910K ﹤0.01% 1826
2021
Q3 		– Sell
-1,600
Closed -$894K – 2344
2021
Q2 		$894K Buy
+1,600
New +$811K ﹤0.01% 1337
2017
Q1 		– Sell
-28,800
Closed -$10.6M – 1755
2016
Q4 		$10.6M Buy
+28,800
New +$11M 0.06% 465

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Balyasny Asset Management's REGN Position: Q1 2026 in Review

Balyasny Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 98% in Q1 2026, selling an estimated $51.4M and leaving 1,505 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2022.

Balyasny Asset Management first reported a position in REGN in Q2 2013 and has held it in 27 quarters since. The position peaked at $81.1M in Q2 2019. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Balyasny Asset Management held 1,505 shares of Regeneron Pharmaceuticals worth $1.16M as of Q1 2026.
  • Balyasny Asset Management sold 67,080 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $51.4M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2022 holding.
  • Balyasny Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • Balyasny Asset Management's Regeneron Pharmaceuticals position peaked at $81.1M in Q2 2019.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.